Bortezomib-induced peripheral neuropathy: Clinical features, molecular basis, and therapeutic approach

被引:6
作者
Yang, Yang [1 ,2 ,3 ,5 ]
Zhao, Bing [3 ]
Lan, Hongli [3 ]
Sun, Jinbing [2 ,5 ]
Wei, Guoli [1 ,3 ,4 ,5 ]
机构
[1] Nanjing Univ Chinese Med, Nanjing Lishui Dist Hosp Tradit Chinese Med, Dept Oncol, Nanjing, Peoples R China
[2] Soochow Univ, Changshu Peoples Hosp 1, Dept Gen Surg, Affiliated Changshu Hosp, Changshu, Peoples R China
[3] Nanjing Univ Chinese Med, Affiliated Hosp Integrated Tradit Chinese & Wester, Jiangsu Prov Med Innovat Ctr, Nanjing, Peoples R China
[4] Nanjing Univ Chinese Med, Affiliated Hosp Integrated Tradit Chinese & Wester, Dept Oncol, Nanjing, Peoples R China
[5] Nanjing Lishui Dist Hosp Tradit Chinese Med, Dept Oncol, 201 Wenchang Rd, Nanjing 211200, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
Bortezomib-induced peripheral neuropathy; Clinical features; Pathogenesis; Therapeutic drug development; REFRACTORY MULTIPLE-MYELOMA; CHEMOTHERAPY-INDUCED NEUROPATHY; OPEN-LABEL; INTRAVENOUS BORTEZOMIB; SCHWANN-CELLS; UP-REGULATION; NEUROTOXICITY; PAIN; ACTIVATION; PROTEASOME;
D O I
10.1016/j.critrevonc.2024.104353
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Bortezomib is the first-line standard and most effective chemotherapeutic for multiple myeloma; however, bortezomib-induced peripheral neuropathy (BIPN) severely affects the chemotherapy regimen and has long-term impact on patients under maintenance therapy. The pathogenesis of BIPN is poorly understood, and basic research and development of BIPN management drugs are in early stages. Besides chemotherapy dose reduction and regimen modification, no recommended prevention and treatment approaches are available for BIPN apart from the International Myeloma Working Group guidelines for peripheral neuropathy in myeloma. An in-depth exploration of the pathogenesis of BIPN, development of additional therapeutic approaches, and identification of risk factors are needed. Optimizing effective and standardized BIPN treatment plans and providing more decision-making evidence for clinical diagnosis and treatment of BIPN are necessary. This article reviews the recent advances in BIPN research; provides an overview of clinical features, underlying molecular mechanisms, and therapeutic approaches; and highlights areas for future studies.
引用
收藏
页数:16
相关论文
共 161 条
[51]   Specific Attenuation of Purinergic Signaling during Bortezomib-Induced Peripheral Neuropathy In Vitro [J].
Holzer, Anna-Katharina ;
Suciu, Ilinca ;
Karreman, Christiaan ;
Goj, Thomas ;
Leist, Marcel .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (07)
[52]   Efficacy and safety of subcutaneous versus intravenous bortezomib in multiple myeloma: a meta-analysis [J].
Hu, Bin ;
Zhou, Quan ;
Wu, Tao ;
Zhuang, Lan ;
Yi, Liping ;
Cao, Jinxia ;
Yang, Xin ;
Wang, Jun .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (04) :329-338
[53]   Recent Developments of Novel Pharmacologic Therapeutics for Prevention of Chemotherapy-Induced Peripheral Neuropathy [J].
Hu, Shuiying ;
Huang, Kevin M. ;
Adams, Elizabeth J. ;
Loprinzi, Charles L. ;
Lustberg, Maryam B. .
CLINICAL CANCER RESEARCH, 2019, 25 (21) :6295-6301
[54]   Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice [J].
Huang, Kevin M. ;
Leblanc, Alix F. ;
Uddin, Muhammad Erfan ;
Kim, Ji Young ;
Chen, Mingqing ;
Eisenmann, Eric D. ;
Gibson, Alice A. ;
Li, Yang ;
Hong, Kristen W. ;
DiGiacomo, Duncan ;
Xia, Sherry H. ;
Alberti, Paola ;
Chiorazzi, Alessia ;
Housley, Stephen N. ;
Cope, Timothy C. ;
Sprowl, Jason A. ;
Wang, Jing ;
Loprinzi, Charles L. ;
Noonan, Anne ;
Lustberg, Maryam B. ;
Cavaletti, Guido ;
Pabla, Navjot ;
Hu, Shuiying ;
Sparreboom, Alex .
JOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (09) :4601-4606
[55]   Protection of Bortezomib-induced Neurotoxicity by Antioxidants [J].
Iijima, Yosuke ;
Bandow, Kenjiro ;
Amano, Shigeru ;
Sano, Motohiko ;
Hino, Shunsuke ;
Kaneko, Takahiro ;
Horie, Norio ;
Sakagami, Hiroshi .
ANTICANCER RESEARCH, 2020, 40 (07) :3685-3696
[56]   Bortezornib in recurrent and/or refractory multiple myeloma - Initial clinical experience in patients with impaired renal function [J].
Jagannath, S ;
Barlogie, B ;
Berenson, JR ;
Singhal, S ;
Alexanian, R ;
Srkalovic, G ;
Orlowski, RZ ;
Richardson, PG ;
Anderson, J ;
Nix, D ;
Esseltine, DL ;
Anderson, KC .
CANCER, 2005, 103 (06) :1195-1200
[57]   The Development and Maintenance of Paclitaxel-induced Neuropathic Pain Require Activation of the Sphingosine 1-Phosphate Receptor Subtype 1 [J].
Janes, Kali ;
Little, Joshua W. ;
Li, Chao ;
Bryant, Leesa ;
Chen, Collin ;
Chen, Zhoumou ;
Kamocki, Krzysztof ;
Doyle, Timothy ;
Snider, Ashley ;
Esposito, Emanuela ;
Cuzzocrea, Salvatore ;
Bieberich, Erhard ;
Obeid, Lina ;
Petrache, Irina ;
Nicol, Grant ;
Neumann, William L. ;
Salvemini, Daniela .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (30) :21082-21097
[58]   Higher proteotoxic stress rather than mitochondrial damage is involved in higher neurotoxicity of bortezomib compared to carfilzomib [J].
Jannuzzi, Ayse Tarbin ;
Arslan, Sema ;
Yilmaz, Ayse Mine ;
Sari, Gulce ;
Beklen, Hande ;
Mendez, Lucia ;
Fedorova, Maria ;
Arga, Kazim Yalcin ;
Yilmaz, Betul Karademir ;
Alpertunga, Buket .
REDOX BIOLOGY, 2020, 32
[59]   Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis [J].
Kanbayashi, Yuko ;
Hosokawa, Toyoshi ;
Okamoto, Kousuke ;
Konishi, Hideyuki ;
Otsuji, Eigo ;
Yoshikawa, Toshikazu ;
Takagi, Tatsuya ;
Taniwaki, Masafumi .
ANTI-CANCER DRUGS, 2010, 21 (09) :877-881
[60]   Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer [J].
Kandula, Tejaswi ;
Farrar, Michelle A. ;
Kiernan, Matthew C. ;
Krishnan, Arun V. ;
Goldstein, David ;
Horvath, Lisa ;
Grimison, Peter ;
Boyle, Frances ;
Baron-Hay, Sally ;
Park, Susanna B. .
CLINICAL NEUROPHYSIOLOGY, 2017, 128 (07) :1166-1175